FDA approves Spravato as monotherapy for adults with major depressive disorder
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as monotherapy for adults with treatment-resistant depression, Johnson & Johnson announced in a press release.
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...
We identified 32 studies that met our inclusion criteria. Results: We found that the relative risk of developing a depressive disorder was incidence rate ratio = 0.79 (95% confidence interval ...
What are some ways the brain differs in people with depression? Studies of individuals with major depressive disorder have identified lower gray matter volume in a number of brain areas relative ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback